Reports Q3 revenue $10.2M, consensus $9.9M. Wei-Wu He, Ph.D., CASI‘s Chairman and Chief Executive Officer, commented, "We are pleased to report $10.2 million in EVOMELA(R) sales revenue for the third quarter of 2022. This is a 26% of increase compared to the same period last year. Our teams in both China and US delivered strong performance despite the continued COVID lockdown in several major cities in China. Since the third quarter, the COVID-19 pandemic has gradually spread nationwide in China, with many small to medium-sized cities upgrading their control measures. The implementation of these enhanced pandemic control measures is expected to adversely impact our sales activities for the remainder of the year."
Published first on TheFly
